Korro Bio
NASDAQ: KRROCambridge, US · Founded 2018 · Delaware corporation · 77 employees on LinkedIn · 3 known investors
Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.
Founders & leadership
Korro Bio was founded in 2018 by Nessan Bermingham.
NB
Nessan BerminghamMr. Bermingham is the Executive Chair of the Issuer.
OC
Board
JF
Investors · 3
Reported raises · per SEC filings
Form D private placements$4M disclosed across 1 round · 2019
▶$4MraisedJun 2019 · 1 investors · BiotechnologyRule 506(b)
▶$4MraisedJun 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nessan BerminghamExecutive Officer, Director, Promoter
- Ommer ChohanExecutive Officer, Director, Promoter
- Jean-Francois FormelaDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Bridgebio29 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
bio23 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
Robinhood23 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Korro Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Korro Bio do?
- Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.
- Who founded Korro Bio?
- Korro Bio was founded by Nessan Bermingham in 2018.
- Who are Korro Bio's investors?
- Korro Bio's investors include Atlas Venture, MC Healthcare Ventures, New Enterprise Associates (NEA).
- How much funding has Korro Bio raised?
- Korro Bio has disclosed $4M raised across 1 round.
- Where is Korro Bio headquartered?
- Korro Bio is headquartered in Cambridge, US.